Literature DB >> 9716154

Modulation of plasminogen activator inhibitor 1 by Triton X-100--identification of two consecutive conformational transitions.

A Gils1, P J Declerck.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a unique member of the serpin superfamily because of its conformational and functional flexibility. In the present study, we have evaluated the influence of the non-ionic detergent Triton X-100 (TX-100) on the functional stability and conformational transitions of PAI-1. At 37 degrees C, TX-100 induced a concentration-dependent decrease of the functional half-life of PAI-1 resulting in half-lives of 177 +/- 54 min (mean +/- SD, n = 3), 19 +/- 2 min, 1.7 +/- 0.3 min and 0.53 +/- 0.03 min in the presence of 0.005, 0.010, 0.020 and 0.2% TX-100, respectively, compared to a half-life of 270 +/- 146 min in the absence of TX-100. Conformational analysis at various time points and at different temperatures (0 degrees C, 25 degrees C, 37 degrees C) revealed that this inactivation proceeds through the formation of a substrate-like intermediate followed by the formation of the latent form. Kinetic evaluation demonstrated that this conversion fits to two consecutive first-order transitions, i.e. active k1--> substrate k2--> latent. The k1 value was strongly dependent on the concentration of TX-100 (e.g. 0.002 +/- 0.0006 s(-1) and 0.029 +/- 0.003 s(-1) for 0.01% and 0.2% TX-100 at 37 degrees C) whereas the conversion of substrate to latent (k2) was virtually independent of the TX-100 concentration (i.e. 0.012 +/- 0.002 s(-1) and 0.011 +/- 0.001 s(-1) for 0.01 and 0.2% TX-100 at 37 degrees C). Experiments with a variety of other non-ionic amphiphilic compounds revealed that the amphiphilic character of the compound is, at least in part, responsible for the observed effects and strongly indicate that the currently reported mechanism of inactivation is of general importance for the conformational transitions in PAI-1. In conclusion, TX- 100 changes the initial conformation of PAI-1 resulting in altered functional properties. This observation allows us to develop a new model for the mechanism involved in the conformational flexibility of PAI-1 and may provide new insights for the development of strategies for interference with PAI-1 activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716154

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.

Authors:  Jan K Jensen; Anders Malmendal; Birgit Schiøtt; Sune Skeldal; Katrine E Pedersen; Leyla Celik; Niels Chr Nielsen; Peter A Andreasen; Troels Wind
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

2.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

3.  Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Authors:  Anja P Einholm; Katrine E Pedersen; Troels Wind; Paulina Kulig; Michael T Overgaard; Jan K Jensen; Julie S Bødker; Anni Christensen; Peter Charlton; Peter A Andreasen
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

4.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05

5.  Platelets retain high levels of active plasminogen activator inhibitor 1.

Authors:  Helén Brogren; Karin Wallmark; Johanna Deinum; Lena Karlsson; Sverker Jern
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 6.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

7.  Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.

Authors:  Richard G Jung; Pouya Motazedian; F Daniel Ramirez; Trevor Simard; Pietro Di Santo; Sarah Visintini; Mohammad Ali Faraz; Alisha Labinaz; Young Jung; Benjamin Hibbert
Journal:  Thromb J       Date:  2018-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.